Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival—up to two years—among patients prescribed two of the most widely used drugs in a class of anticancer ...
Sep 5, 2013
0
0
Although previous research has linked alcohol consumption to an increased risk of developing breast cancer, a new study has found that drinking before and after diagnosis does not impact survival from the disease. In fact, ...
Apr 8, 2013
0
0
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, ...
Dec 7, 2012
0
1
The use of contralateral prophylactic mastectomy (CPM), the surgical removal of a breast unaffected by cancer as part of the course of treatment for breast cancer, has more than tripled from 2002 to 2012 despite evidence ...
Mar 11, 2016
0
3
Taking low doses of aspirin (which inhibits platelet function) after a colon cancer diagnosis appears to be associated with better survival if the tumor cells express HLA class I antigen.
Mar 31, 2014
0
0
Researchers report that low levels of sodium in the blood, known as hyponatremia, increase the risk of dying for patients on the liver transplant waiting list. The study published in Liver Transplantation, a journal of the ...
Jan 27, 2015
0
3
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.
Aug 16, 2012
0
0
(HealthDay)—There appears to be a survival benefit for individuals with early-onset colorectal cancer (CRC) compared with diagnosis at later ages, according to a study published online June 16 in JAMA Network Open.
Jun 17, 2021
0
1
Researchers at Moffitt Cancer Center studied patients with metastatic gastric cancer and found that those who have both surgery and radiation have better survival than those who receive one or no form of treatment.
Feb 27, 2013
0
0
Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a study ...
Sep 21, 2023
0
16
